SCHEMBL20552120

SCHEMBL20552120

Cc1c(-c2ccccc2Nc2cccc(C(F)(F)F)c2)cnn1CCO

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ YAP1 P46937 1/20 0.46
▸ TEAD4 Q15561 1/20 0.46
▸ TEAD2 Q15562 1/20 0.46
▸ LMNA P02545 3/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ GAA P10253 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ CYP1A2 P05177 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ RXFP1 Q9HBX9 1/20 0.42
▸ DHODH Q02127 1/20 0.42
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ FGFR1 P11362 1/20 0.41
▸ DDR2 Q16832 1/20 0.41
▸ RECQL P46063 1/20 0.41
▸ IDH2 P48735 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20552900 0.88 ABL1 (0.38) YAP1GAAMAPTRAB9ADHODH
SCHEMBL20551966 0.86 YAP1 (0.49) YAP1TEAD4TEAD2LMNAMAPT
SCHEMBL20553653 0.82 YAP1 (0.46) YAP1TEAD4TEAD2LMNAALDH1A1
SCHEMBL21749237 0.82 ALDH1A1 (0.44) YAP1TEAD4TEAD2LMNAALDH1A1
SCHEMBL20552230 0.82 ALDH1A1 (0.45) YAP1TEAD4TEAD2LMNAALDH1A1
SCHEMBL25786915 0.82 ABL1 (0.37) LMNAALDH1A1GAAMAPTRAB9A
SCHEMBL21749289 0.82 PDK2 (0.50) YAP1TEAD4TEAD2ALDH1A1GAA
SCHEMBL25786986 0.80 KCNK18 (0.40) YAP1TEAD4TEAD2LMNAALDH1A1
SCHEMBL20553228 0.77 ALDH1A1 (0.46) YAP1TEAD4TEAD2LMNAALDH1A1
SCHEMBL21749308 0.77 ALDH1A1 (0.46) YAP1TEAD4TEAD2LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192607-A1 TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-06-22 — — US disclosed
US-11186554-B2 Non-fused tricyclic compounds VIVACE THERAPEUTICS, INC. (US) 2021-11-30 — — US disclosed
US-11186554-B2 Non-fused tricyclic compounds VIVACE THERAPEUTICS, INC. (US) 2021-11-30 — — US disclosed
CN-111132673-A Non-fused tricyclic compounds 维瓦斯治疗公司 2020-05-08 — — CN disclosed
EP-3618818-A1 NON-FUSED TRICYCLIC COMPOUNDS Vivace Therapeutics, Inc. (US) 2020-03-11 — — EP disclosed
US-20200062721-A1 NON-FUSED TRICYCLIC COMPOUNDS VIVACE THERAPEUTICS, INC. 2020-02-27 — — US disclosed
US-20200062721-A1 NON-FUSED TRICYCLIC COMPOUNDS VIVACE THERAPEUTICS, INC. 2020-02-27 — — US disclosed
WO-2018204532-A1 NON-FUSED TRICYCLIC COMPOUNDS VIVACE THERAPEUTICS, INC. (US) 2018-11-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200062721-A1 NON-FUSED TRICYCLIC COMPOUNDS YAP1, MYC, TEAD2 YAP1 1/4885TEAD4 7/4885TEAD2 3/4885
US-11186554-B2 Non-fused tricyclic compounds YAP1, MYC, TEAD2 YAP1 1/4885TEAD4 7/4885TEAD2 3/4885
US-20230192607-A1 TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF TEAD1, TEAD4, TEAD2 YAP1 9/4885TEAD4 2/4885TEAD2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback